EcoDrugPlus

Potassium Voltage-Gated Channel Subfamily D Member 3-Like

Ensembl ID : ENSNFUG00015022902
Gene Symbol: LOC107385359
3 Cross references
192 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Kqt Member 2-Like

Ensembl ID : ENSNFUG00015010920
Gene Symbol: LOC107384874
3 Cross references
185 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 3

Ensembl ID : ENSNFUG00015021351
Gene Symbol: KCNQ3
1 Cross references
191 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 5

Ensembl ID : ENSNFUG00015007192
Gene Symbol: KCNQ5
1 Cross references
191 Possible Orthologues:

Potassium Voltage-Gated Channel, Kqt-Like Subfamily, Member 2a

Ensembl ID : ENSNFUG00015005616
Gene Symbol: KCNQ2A
1 Cross references
185 Possible Orthologues:

Presenilin 2

Ensembl ID : ENSNFUG00015001918
Gene Symbol: PSEN2
3 Cross references
205 Possible Orthologues:

Presenilin Enhancer, Gamma-Secretase Subunit

Ensembl ID : ENSNFUG00015013637
Gene Symbol: PSENEN
3 Cross references
183 Possible Orthologues:

Presenilin-1-Like

Ensembl ID : ENSNFUG00015006372
Gene Symbol: LOC107391854
3 Cross references
200 Possible Orthologues:

Primary Amine Oxidase, Liver Isozyme-Like

Ensembl ID : ENSNFUG00015005121
Gene Symbol: LOC107391824
3 Cross references
404 Possible Orthologues:

Probable Histone Deacetylase 1-B

Ensembl ID : ENSNFUG00015020889
Gene Symbol: LOC107397144
3 Cross references
234 Possible Orthologues:

Progesterone Receptor

Ensembl ID : ENSNFUG00015006578
Gene Symbol: PGR
3 Cross references
193 Possible Orthologues:

Prostaglandin D2 Receptor 2

Ensembl ID : ENSNFUG00015004221
Gene Symbol: PTGDR2
1 Cross references
145 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).